Skip to main content

Table 1 Patients’ characteristics by cardiometabolic profiles created in latent profile analysis (N = 147)

From: Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysis

Variables

Total (N = 147)

Median [P25; P75]

or n (%)

Profile 1 (n = 16)

Median [P25; P75]

or n (%)

Profile 2 (n = 14)

Median [P25; P75]

or n (%)

Profile 3 (n = 23)

Median [P25; P75]

or n (%)

Profile 4 (n = 29)

Median [P25; P75]

or n (%)

Profile 5 (n = 28)

Median [P25; P75]

or n (%)

Profile 6 (n = 37)

Median [P25; P75]

or n (%)

P-value

Characteristics at the time of the last consultation

 Age, in years

80.0 [77.0; 83.0]

80.5 [76.0; 82.8]

80.0 [78.0; 84.0]

77.0 [76.0; 81.0]

79.0 [76.0; 82.0]

80.0 [77.0; 83.8]

81.0 [77.0; 84.0]

0.545

 Women

55 (37.4)

6 (37.5)

4 (28.6)

12 (52.2)

14 (48.3)

7 (25.0)

12 (32.4)

0.278

 Family history of diabetes*

52 (35.4)

4 (25.0)

4 (30.8)

5 (21.7)

11 (37.9)

11 (39.3)

17 (49.6)

0.348

 Diabetes duration, in years

19.0 [12.0; 27.0]

12.0 [3.3; 14.8]

15.0 [9.8; 20.3]

12.0 [5.0; 23.0]

20.0 [15.5; 28.0]

23.5 [17.3; 29.0]

22.0 [14.5; 27.5]

< 0.001

Characteristics at the time of HOMA2

 Age at HOMA2, in years

72.0 [69.0; 76.0]

73.5 [70.3; 76.5]

72.0 [70.0; 73.3]

71.0 [64.0; 76.0]

71.0 [66.0; 77.0]

71.0 [68.3; 74.8]

73.0 [68.0; 77.0]

0.714

 BMI, in kg/m2

28.3 [25.7; 31.2]

26.8 [24.9; 29.6]

26.2 [24.7; 33.1]

28.0 [25.8; 33.3]

29.6 [26.6; 34.6]

27.9 [25.7; 29.6]

28.2 [25.5; 31.7]

0.037

  BMI [18–25[kg/m2

33 (22.4)

4 (25.0)

5 (35.7)

3 (13.0)

8 (27.6)

9 (32.1)

4 (10.8)

 

  BMI [25–30[kg/m2

68 (46.3)

10 (62.5)

6 (42.9)

9 (39.1)

8 (27.6)

14 (50.0)

21 (56.8)

 

  BMI ≥30 kg/m2

45 (30.6)

2 (12.5)

3 (21.4)

11 (47.8)

13 (44.8)

4 (14.3)

12 (32.4)

 

 HbA1c†, in %

7.1 [6.4; 8.2]

6.6 [6.0; 7.9]

5.4 [5.2; 6.6]

7.0 [6.4; 7.9]

7.4 [7.1; 8.0]

6.8 [5.8; 7.2]

8.4 [7.8; 9.1]

< 0.001

Indicators used in latent profile analysis

 Age at diagnosis, in years

62.0 [54.0; 70.0]

70.5 [63.3; 74.0]

68.0 [61.0; 70.5]

64.0 [58.0; 74.0]

58.0 [54.5; 62.0]

55.5 [47.8; 67.8]

61.0 [52.0; 65.0]

< 0.001‡

 HOMA2%-S, in %

47.4 [32.1; 73.0]

50.5 [47.0; 56.4]

84.1 [58.2; 115.8]

22.3 [15.1; 31.4]

35.2 [29.1; 42.9]

86.3 [74.1; 106.9]

48.3 [34.3; 40.2]

< 0.001‡

 HOMA2%-β, in %

49.3 [32.4; 72.6]

71.6 [68.1; 76.1]

66.5 [47.6; 111.1]

111.6 [95.1; 135.5]

56.5 [46.8; 65.5]

39.2 [32.0; 47.9]

27.3 [21.7; 34.9]

< 0.001‡

 HOMA2%-βxS, in %

25.0 [16.0; 37.0]

36.0 [33.3; 40.5]

56.0 [52.8; 64.3]

28.0 [17.0; 34.0]

20.0 [17.0; 24.0]

34.5 [28.3; 39.8]

13.0 [9.0; 16.0]

< 0.001‡

  1. HOMA2%-S: insulin sensitivity assessed by Homeostasis Model Assessment 2 (HOMA2); HOMA2%-β: beta-cell function assessed by HOMA2; HOMA2%-βxS: Hyperbolic product between beta-cell function and insulin sensitivity. BMI: body mass index (kg.m−2).* 3 missing values (2.0%). † 1 missing value (0.7%). ‡ Differences were expected as these indicators were included in the LPA to create the 6 profiles